Get NF-%CE%BAB essential facts below. View Videos or join the NF-%CE%BAB discussion. Add NF-%CE%BAB to your Like2do.com topic list for future reference or share this resource on social media.
Mechanism of NF-?B action. In this figure, the NF-?B heterodimer consisting of Rel and p50 proteins is used as an example. While in an inactivated state, NF-?B is located in the cytosol complexed with the inhibitory protein I?B?. Through the intermediacy of integral membrane receptors, a variety of extracellular signals can activate the enzyme I?B kinase (IKK). IKK, in turn, phosphorylates the I?B? protein, which results in ubiquitination, dissociation of I?B? from NF-?B, and eventual degradation of I?B? by the proteasome. The activated NF-?B is then translocated into the nucleus where it binds to specific sequences of DNA called response elements (RE). The DNA/NF-?B complex then recruits other proteins such as coactivators and RNA polymerase, which transcribe downstream DNA into mRNA. In turn, mRNA is translated into protein, resulting in a change of cell function.
Schematic diagram of NF-?B protein structure. There are two structural classes of NF-?B proteins: class I (top) and class II (bottom). Both classes of proteins contain a N-terminalDNA-binding domain (DBD), which also serves as a dimerization interface to other NF-?B transcription factors and, in addition, binds to the inhibitory I?B? protein. The C-terminus of class I proteins contains a number of ankyrin repeats and has transrepression activity. In contrast, the C-terminus of class II proteins has a transactivation function.
All proteins of the NF-?B family share a Rel homology domain in their N-terminus. A subfamily of NF-?B proteins, including RelA, RelB, and c-Rel, have a transactivation domain in their C-termini. In contrast, the NF-?B1 and NF-?B2 proteins are synthesized as large precursors, p105, and p100, which undergo processing to generate the mature NF-?B subunits, p50 and p52, respectively. The processing of p105 and p100 is mediated by the ubiquitin/proteasome pathway and involves selective degradation of their C-terminal region containing ankyrin repeats. Whereas the generation of p52 from p100 is a tightly regulated process, p50 is produced from constitutive processing of p105. The p50 and p52 proteins have no intrinsic ability to activate transcription and thus have been proposed to act as transcriptional repressors when binding ?B elements as homodimers. Indeed, this confounds the interpretation of p105-knockout studies, where the genetic manipulation is removing an I?B (full-length p105) and a likely repressor (p50 homodimers) in addition to a transcriptional activator (the RelA-p50 heterodimer).
NF-?B family members share structural homology with the retroviral oncoprotein v-Rel, resulting in their classification as NF-?B/Rel proteins.
There are five proteins in the mammalian NF-?B family:
NF-?B (green) heterodimerizes with RelB (cyan) to form a ternary complex with DNA (orange) that promotes gene transcription.
NF-?B is important in regulating cellular responses because it belongs to the category of "rapid-acting" primary transcription factors, i.e., transcription factors that are present in cells in an inactive state and do not require new protein synthesis in order to become activated (other members of this family include transcription factors such as c-Jun, STATs, and nuclear hormone receptors). This allows NF-?B to be a first responder to harmful cellular stimuli. Known inducers of NF-?B activity are highly variable and include reactive oxygen species (ROS), tumor necrosis factor alpha (TNF?), interleukin 1-beta (IL-1?), bacterial lipopolysaccharides (LPS), isoproterenol, cocaine, and ionizing radiation.
Receptor activator of NF-?B (RANK), which is a type of TNFR, is a central activator of NF-?B. Osteoprotegerin (OPG), which is a decoy receptorhomolog for RANK ligand (RANKL), inhibits RANK by binding to RANKL, and, thus, osteoprotegerin is tightly involved in regulating NF-?B activation.
Many bacterial products and stimulation of a wide variety of cell-surface receptors lead to NF-?B activation and fairly rapid changes in gene expression. The identification of Toll-like receptors (TLRs) as specific pattern recognition molecules and the finding that stimulation of TLRs leads to activation of NF-?B improved our understanding of how different pathogens activate NF-?B. For example, studies have identified TLR4 as the receptor for the LPS component of Gram-negative bacteria. TLRs are key regulators of both innate and adaptive immune responses.
Unlike RelA, RelB, and c-Rel, the p50 and p52 NF-?B subunits do not contain transactivation domains in their C terminal halves. Nevertheless, the p50 and p52 NF-?B members play critical roles in modulating the specificity of NF-?B function. Although homodimers of p50 and p52 are, in general, repressors of ?B site transcription, both p50 and p52 participate in target gene transactivation by forming heterodimers with RelA, RelB, or c-Rel. In addition, p50 and p52 homodimers also bind to the nuclear protein Bcl-3, and such complexes can function as transcriptional activators.
In unstimulated cells, the NF-?B dimers are sequestered in the cytoplasm by a family of inhibitors, called I?Bs (Inhibitor of ?B), which are proteins that contain multiple copies of a sequence called ankyrin repeats. By virtue of their ankyrin repeat domains, the I?B proteins mask the nuclear localization signals (NLS) of NF-?B proteins and keep them sequestered in an inactive state in the cytoplasm.
I?Bs are a family of related proteins that have an N-terminal regulatory domain, followed by six or more ankyrin repeats and a PEST domain near their C terminus. Although the I?B family consists of I?B?, I?B?, I?B?, and Bcl-3, the best-studied and major I?B protein is I?B?. Due to the presence of ankyrin repeats in their C-terminal halves, p105 and p100 also function as I?B proteins. The c-terminal half of p100, that is often referred to as I?B?, also functions as an inhibitor. I?B? degradation in response to developmental stimuli, such as those transduced through LT?R, potentiate NF-?B dimer activation in a NIK dependent non-canonical pathway.
Activation process (canonical/classical)
Activation of the NF-?B is initiated by the signal-induced degradation of I?B proteins. This occurs primarily via activation of a kinase called the I?B kinase (IKK). IKK is composed of a heterodimer of the catalytic IKK? and IKK? subunits and a "master" regulatory protein termed NEMO (NF-?B essential modulator) or IKK gamma. When activated by signals, usually coming from the outside of the cell, the I?B kinase phosphorylates two serine residues located in an I?B regulatory domain. When phosphorylated on these serines (e.g., serines 32 and 36 in human I?B?), the I?B proteins are modified by a process called ubiquitination, which then leads them to be degraded by a cell structure called the proteasome.
With the degradation of I?B, the NF-?B complex is then freed to enter the nucleus where it can 'turn on' the expression of specific genes that have DNA-binding sites for NF-?B nearby. The activation of these genes by NF-?B then leads to the given physiological response, for example, an inflammatory or immune response, a cell survival response, or cellular proliferation. Translocation of NF-?B to nucleus can be detected immunocytochemically and measured by laser scanning cytometry. NF-?B turns on expression of its own repressor, I?B?. The newly synthesized I?B? then re-inhibits NF-?B and, thus, forms an auto feedback loop, which results in oscillating levels of NF-?B activity. In addition, several viruses, including the AIDS virus HIV, have binding sites for NF-?B that controls the expression of viral genes, which in turn contribute to viral replication or viral pathogenicity. In the case of HIV-1, activation of NF-?B may, at least in part, be involved in activation of the virus from a latent, inactive state. YopP is a factor secreted by Yersinia pestis, the causative agent of plague, that prevents the ubiquitination of I?B. This causes this pathogen to effectively inhibit the NF-?B pathway and thus block the immune response of a human infected with Yersinia.
Inhibitors of NF-?B activity
Concerning known protein inhibitors of NF-?B activity, one of them is IFRD1, which represses the activity of NF-?B p65 by enhancing the HDAC-mediated deacetylation of the p65 subunit at lysine 310, by favoring the recruitment of HDAC3 to p65. In fact IFRD1 forms trimolecular complexes with p65 and HDAC3.
The NAD+-dependent protein deacetylase and longevity factor SIRT1 inhibits NF-?B gene expression by deacetylating the RelA/p65 subunit of NF-kB at lysine 310.
A select set of cell-differentiating or developmental stimuli, such as lymphotoxin ?-receptor (LT?R), BAFF or RANKL, activate the non-canonical NF-?B pathway to induce NF-?B/RelB:p52 dimer in the nucleus. In this pathway, activation of the NF-?B inducing kinase (NIK) upon receptor ligation led to the phosphorylation and subsequent proteasomal processing of the NF-?B2 precursor protein p100 into mature p52 subunit in an IKK1/IKKa dependent manner. Then p52 dimerizes with RelB to appear as a nuclear RelB:p52 DNA binding activity and regulate a distinct class of genes. In contrast to the canonical signaling that relies upon NEMO-IKK2 mediated degradation of I?B?, -?, -?, the non-canonical signaling critically depends on NIK mediated processing of p100 into p52. Given their distinct regulations, these two pathways were thought to be independent of each other. However, recent analyses revealed that synthesis of the constituents of the non-canonical pathway, viz RelB and p52, is controlled by the canonical IKK2-I?B-RelA:p50 signaling. Moreover, generation of the canonical and non-canonical dimers, viz RelA:p50 and RelB:p52, within the cellular milieu are also mechanistically interlinked. These analyses suggest that an integrated NF-?B system network underlies activation of both RelA and RelB containing dimer and that a malfunctioning canonical pathway will lead to an aberrant cellular response also through the non-canonical pathway.
NF-?B is a major transcription factor that regulates genes responsible for both the innate and adaptive immune response. Upon activation of either the T- or B-cell receptor, NF-?B becomes activated through distinct signaling components. Upon ligation of the T-cell receptor, protein kinase Lck is recruited and phosphorylates the ITAMs of the CD3 cytoplasmic tail. ZAP70 is then recruited to the phosphorylated ITAMs and helps recruit LAT and PLC-?, which causes activation of PKC. Through a cascade of phosphorylation events, the kinase complex is activated and NF-?B is able to enter the nucleus to upregulate genes involved in T-cell development, maturation, and proliferation.
In the nervous system
In addition to roles in mediating cell survival, studies by Mark Mattson and others have shown that NF-?B has diverse functions in the nervous system including roles in plasticity, learning, and memory. In addition to stimuli that activate NF-?B in other tissues, NF-?B in the nervous system can be activated by Growth Factors (BDNF, NGF) and synaptic transmission such as glutamate. These activators of NF-?B in the nervous system all converge upon the IKK complex and the canonical pathway.
Recently there has been a great deal of interest in the role of NF-?B in the nervous system. Current studies suggest that NF-?B is important for learning and memory in multiple organisms including crabs, fruit flies, and mice. NF-?B may regulate learning and memory in part by modulating synaptic plasticity, synapse function, as well as by regulating the growth of dendrites and dendritic spines.
Genes that have NF-?B binding sites are shown to have increased expression following learning, suggesting that the transcriptional targets of NF-?B in the nervous system are important for plasticity. Many NF-?B target genes that may be important for plasticity and learning include growth factors (BDNF, NGF) cytokines (TNF-alpha, TNFR) and kinases (PKAc).
Despite the functional evidence for a role for Rel-family transcription factors in the nervous system, it is still not clear that the neurological effects of NF-?B reflect transcriptional activation in neurons. Most manipulations and assays are performed in the mixed-cell environments found in vivo, in "neuronal" cell cultures that contain significant numbers of glia, or in tumor-derived "neuronal" cell lines. When transfections or other manipulations have been targeted specifically at neurons, the endpoints measured are typically electrophysiology or other parameters far removed from gene transcription. Careful tests of NF-?B-dependent transcription in highly purified cultures of neurons generally show little to no NF-?B activity. Some of the reports of NF-?B in neurons appear to have been an artifact of antibody nonspecificity. Of course, artifacts of cell culture--e.g., removal of neurons from the influence of glia--could create spurious results as well. But this has been addressed in at least two coculture approaches. Moerman et al. used a coculture format whereby neurons and glia could be separated after treatment for EMSA analysis, and they found that the NF-?B induced by glutamatergic stimuli was restricted to glia (and, intriguingly, only glia that had been in the presence of neurons for 48 hours). The same investigators explored the issue in another approach, utilizing neurons from an NF-?B reporter transgenic mouse cultured with wild-type glia; glutamatergic stimuli again failed to activate in neurons. Some of the DNA-binding activity noted under certain conditions (particularly that reported as constitutive) appears to result from Sp3 and Sp4 binding to a subset of ?B enhancer sequences in neurons. This activity is actually inhibited by glutamate and other conditions that elevate intraneuronal calcium. In the final analysis, the role of NF-?B in neurons remains opaque due to the difficulty of measuring transcription in cells that are simultaneously identified for type. Certainly, learning and memory could be influenced by transcriptional changes in astrocytes and other glial elements. And it should be considered that there could be mechanistic effects of NF-?B aside from direct transactivation of genes.
Overview of signal transduction pathways involved in apoptosis.
NF-?B is widely used by eukaryotic cells as a regulator of genes that control cell proliferation and cell survival. As such, many different types of human tumors have misregulated NF-?B: that is, NF-?B is constitutively active. Active NF-?B turns on the expression of genes that keep the cell proliferating and protect the cell from conditions that would otherwise cause it to die via apoptosis. In cancer, proteins that control NF-?B signaling are mutated or aberrantly expressed, leading to defective coordination between the malignant cell and the rest of the organism. This is evident both in metastasis, as well as in the inefficient eradication of the tumor by the immune system.
Normal cells can die when removed from the tissue they belong to, or when their genome cannot operate in harmony with tissue function: these events depend on feedback regulation of NF-?B, and fail in cancer.
Defects in NF-?B results in increased susceptibility to apoptosis leading to increased cell death. This is because NF-?B regulates anti-apoptotic genes especially the TRAF1 and TRAF2 and therefore abrogates the activities of the caspase family of enzymes, which are central to most apoptotic processes.
In tumor cells, NF-?B is active (for example, in 41% of Nasopharyngeal carcinoma) either due to mutations in genes encoding the NF-?B transcription factors themselves or in genes that control NF-?B activity (such as I?B genes); in addition, some tumor cells secrete factors that cause NF-?B to become active. Blocking NF-?B can cause tumor cells to stop proliferating, to die, or to become more sensitive to the action of anti-tumor agents. Thus, NF-?B is the subject of much active research among pharmaceutical companies as a target for anti-cancer therapy.
However, even though convincing experimental data have identified NF-?B as a critical promoter of tumorigenesis, which creates a solid rationale for the development of antitumor therapy that is based upon suppression of NF-?B activity, caution should be exercised when considering anti-NF-?B activity as a broad therapeutic strategy in cancer treatment as data has also shown that NF-?B activity enhances tumor cell sensitivity to apoptosis and senescence. In addition, it has been shown that canonical NF-?B is a Fas transcription activator and the alternative NF-?B is a Fas transcription repressor. Therefore, NF-?B promotes Fas-mediated apoptosis in cancer cells, and thus inhibition of NF-?B may suppress Fas-mediated apoptosis to impair host immune cell-mediated tumor suppression.
Because NF-?B controls many genes involved in inflammation, it is not surprising that NF-?B is found to be chronically active in many inflammatory diseases, such as inflammatory bowel disease, arthritis, sepsis, gastritis, asthma, atherosclerosis and others. It is important to note though, that elevation of some NF-?B activators, such as osteoprotegerin (OPG), are associated with elevated mortality, especially from cardiovascular diseases. Elevated NF-?B has also been associated with schizophrenia. Recently, NF-?B activation has been suggested as a possible molecular mechanism for the catabolic effects of cigarette smoke in skeletal muscle and sarcopenia.
Research has shown that during inflammation the function of a cell depends on signals it activates in response to contact with adjacent cells and to combinations of hormones, especially cytokines that act on it through specific receptors. A cells' phenotype within a tissue develops through mutual stimulation of feedback signals that coordinate its function with other cells; this is especially evident during reprogramming of cell function when a tissue is exposed to inflammation, because cells alter their phenotype, and gradually express combinations of genes that prepare the tissue for regeneration after the cause of inflammation is removed. Particularly important are feedback responses that develop between tissue resident cells, and circulating cells of the immune system. Fidelity of feedback responses between diverse cell types and the immune system depends on the integrity of mechanisms that limit the range of genes activated by NF-?B, allowing only expression of genes which contribute to an effective immune response and subsequently, a complete restoration of tissue function after resolution of inflammation. In cancer, mechanisms that regulate gene expression in response to inflammatory stimuli are altered to the point that a cell ceases to link its survival with the mechanisms that coordinate its phenotype and its function with the rest of the tissue. This is often evident in severely compromised regulation of NF-?B activity, which allows cancer cells to express abnormal cohorts of NF-?B target genes. This results in not only the cancer cells functioning abnormally: cells of surrounding tissue alter their function and cease to support the organism exclusively. Additionally, several types of cells in the microenvironment of cancer may change their phenotypes to support cancer growth. Inflammation, therefore, is a process that tests the fidelity of tissue components because the process that leads to tissue regeneration requires coordination of gene expression between diverse cell types.
NEMO deficiency syndrome is a rare genetic condition relating to a fault in IKBKG that in turn activates NF-kB. It mostly affects males and has a highly variable set of symptoms and prognoses.
• GluR1 synaptic protein phosphorylation • Expansion of NAcc dendritic processes
Decreased drug reward (net effect)
Many natural products (including anti-oxidants) that have been promoted to have anti-cancer and anti-inflammatory activity have also been shown to inhibit NF-?B. There is a controversial US patent (US patent 6,410,516) that applies to the discovery and use of agents that can block NF-?B for therapeutic purposes. This patent is involved in several lawsuits, including Ariad v. Lilly. Recent work by Karin, Ben-Neriah and others has highlighted the importance of the connection between NF-?B, inflammation, and cancer, and underscored the value of therapies that regulate the activity of NF-?B.
Extracts from a number of herbs and dietary plants are efficient inhibitors of NF-?B activation in vitro.
Aberrant activation of NF-?B is frequently observed in many cancers. Moreover, suppression of NF-?B limits the proliferation of cancer cells. In addition, NF-?B is a key player in the inflammatory response. Hence methods of inhibiting NF-?B signaling has potential therapeutic application in cancer and inflammatory diseases.
The discovery that activation of NF-?B nuclear translocation can be separated from the elevation of oxidant stress gives a promising avenue of development for strategies targeting NF-?B inhibition.
A new drug called denosumab acts to raise bone mineral density and reduce fracture rates in many patient sub-groups by inhibiting RANKL. RANKL acts through its receptor RANK, which in turn promotes NF-?B,
RANKL normally works by enabling the differentiation of osteoclasts from monocytes.
Disulfiram, olmesartan and dithiocarbamates can inhibit the nuclear factor-?B (NF-?B) signaling cascade. Effort to develop direct NF-kB inhibitor has emerged with compounds such as (-)-DHMEQ, PBS-1086, IT-603 and IT-901. (-)-DHMEQ and PBS-1086 are irreversible binder to NF-KB while IT-603 and IT-901 are reversible binder. DHMEQ covalently binds to Cys 38 of p65.
Anatabine's antiinflammatory effects are claimed to result from modulation of NF-?B activity. However the studies purporting its benefit use abnormally high doses in the millimolar range (similar to the extracellular potassium concentration), which are unlikely to be achieved in humans.
BAY 11-7082 has also been identified as a drug that can inhibit the NF-kB signaling cascade. It is capable of preventing the phosphorylation of IKK-? in an irreversible manner such that there is down regulation of NF-kB activation. In has been shown that administration of BAY 11-7082 rescued renal functionality in diabetic-induced Sprague-Dawley rats by suppressing NF-kB regulated oxidative stress.
The biological target of iguratimod, a drug marketed to treat rheumatoid arthritis in Japan and China, was unknown as of 2015, but the primary mechanism of action appeared to be preventing NF-?B activation.
^ abcMeffert MK, Chang JM, Wiltgen BJ, Fanselow MS, Baltimore D (October 2003). "NF-kappa B functions in synaptic signaling and behavior". Nature Neuroscience. 6 (10): 1072-8. doi:10.1038/nn1110. PMID12947408.
^ abcLevenson JM, Choi S, Lee SY, Cao YA, Ahn HJ, Worley KC, Pizzi M, Liou HC, Sweatt JD (April 2004). "A bioinformatics analysis of memory consolidation reveals involvement of the transcription factor c-rel". The Journal of Neuroscience. 24 (16): 3933-43. doi:10.1523/JNEUROSCI.5646-03.2004. PMID15102909.
^ abFreudenthal R, Locatelli F, Hermitte G, Maldonado H, Lafourcade C, Delorenzi A, Romano A (February 1998). "Kappa-B like DNA-binding activity is enhanced after spaced training that induces long-term memory in the crab Chasmagnathus". Neuroscience Letters. 242 (3): 143-6. doi:10.1016/S0304-3940(98)00059-7. PMID9530926.
^Senftleben U, Cao Y, Xiao G, Greten FR, Krähn G, Bonizzi G, Chen Y, Hu Y, Fong A, Sun SC, Karin M (August 2001). "Activation by IKKalpha of a second, evolutionary conserved, NF-kappa B signaling pathway". Science. 293 (5534): 1495-9. doi:10.1126/science.1062677. PMID11520989.
^Guan H, Hou S, Ricciardi RP (March 2005). "DNA binding of repressor nuclear factor-kappaB p50/p50 depends on phosphorylation of Ser337 by the protein kinase A catalytic subunit". The Journal of Biological Chemistry. 280 (11): 9957-62. doi:10.1074/jbc.m412180200. PMID15642694.
^Baud'huin M, Lamoureux F, Duplomb L, Rédini F, Heymann D (September 2007). "RANKL, RANK, osteoprotegerin: key partners of osteoimmunology and vascular diseases". Cellular and Molecular Life Sciences. 64 (18): 2334-50. doi:10.1007/s00018-007-7104-0. PMID17530461.
^Doyle SL, O'Neill LA (October 2006). "Toll-like receptors: from the discovery of NFkappaB to new insights into transcriptional regulations in innate immunity". Biochemical Pharmacology. 72 (9): 1102-13. doi:10.1016/j.bcp.2006.07.010. PMID16930560.
^Li Q, Verma IM (October 2002). "NF-kappaB regulation in the immune system". Nature Reviews. Immunology. 2 (10): 725-34. doi:10.1038/nri910. PMID12360211.
^Fujita T, Nolan GP, Liou HC, Scott ML, Baltimore D (July 1993). "The candidate proto-oncogene bcl-3 encodes a transcriptional coactivator that activates through NF-kappa B p50 homodimers". Genes & Development. 7 (7B): 1354-63. doi:10.1101/gad.7.7b.1354. PMID8330739.
^Franzoso G, Bours V, Park S, Tomita-Yamaguchi M, Kelly K, Siebenlist U (September 1992). "The candidate oncoprotein Bcl-3 is an antagonist of p50/NF-kappa B-mediated inhibition". Nature. 359 (6393): 339-42. doi:10.1038/359339a0. PMID1406939.
^Bours V, Franzoso G, Azarenko V, Park S, Kanno T, Brown K, Siebenlist U (March 1993). "The oncoprotein Bcl-3 directly transactivates through kappa B motifs via association with DNA-binding p50B homodimers". Cell. 72 (5): 729-39. doi:10.1016/0092-8674(93)90401-B. PMID8453667.
^Nelson DE, Ihekwaba AE, Elliott M, Johnson JR, Gibney CA, Foreman BE, Nelson G, See V, Horton CA, Spiller DG, Edwards SW, McDowell HP, Unitt JF, Sullivan E, Grimley R, Benson N, Broomhead D, Kell DB, White MR (October 2004). "Oscillations in NF-kappaB signaling control the dynamics of gene expression". Science. 306 (5696): 704-8. doi:10.1126/science.1099962. PMID15499023.
^Adkins I, Schulz S, Borgmann S, Autenrieth IB, Gröbner S (February 2008). "Differential roles of Yersinia outer protein P-mediated inhibition of nuclear factor-kappa B in the induction of cell death in dendritic cells and macrophages". Journal of Medical Microbiology. 57 (Pt 2): 139-44. doi:10.1099/jmm.0.47437-0. PMID18201977.
^Smith EM, Gregg M, Hashemi F, Schott L, Hughes TK (2006-07-01). "Corticotropin Releasing Factor (CRF) activation of NF-kappaB-directed transcription in leukocytes". Cellular and Molecular Neurobiology. 26 (4-6): 1021-36. doi:10.1007/s10571-006-9040-1. PMID16633893.
^Livolsi A, Busuttil V, Imbert V, Abraham RT, Peyron JF (March 2001). "Tyrosine phosphorylation-dependent activation of NF-kappa B. Requirement for p56 LCK and ZAP-70 protein tyrosine kinases". European Journal of Biochemistry. 268 (5): 1508-15. doi:10.1046/j.1432-1327.2001.02028.x. PMID11231305.
^Wang J, Fu XQ, Lei WL, Wang T, Sheng AL, Luo ZG (August 2010). "Nuclear factor kappaB controls acetylcholine receptor clustering at the neuromuscular junction". The Journal of Neuroscience. 30 (33): 11104-13. doi:10.1523/JNEUROSCI.2118-10.2010. PMID20720118.
^Gutierrez H, Hale VA, Dolcet X, Davies A (April 2005). "NF-kappaB signalling regulates the growth of neural processes in the developing PNS and CNS". Development. 132 (7): 1713-26. doi:10.1242/dev.01702. PMID15743881.
^Zaheer A, Yorek MA, Lim R (December 2001). "Effects of glia maturation factor overexpression in primary astrocytes on MAP kinase activation, transcription factor activation, and neurotrophin secretion". Neurochemical Research. 26 (12): 1293-9. doi:10.1023/A:1014241300179. PMID11885780.
^Qiu J, Hu X, Nesic O, Grafe MR, Rassin DK, Wood TG, Perez-Polo JR (July 2004). "Effects of NF-kappaB oligonucleotide "decoys" on gene expression in P7 rat hippocampus after hypoxia/ischemia". Journal of Neuroscience Research. 77 (1): 108-18. doi:10.1002/jnr.20156. PMID15197744.
^Jarosinski KW, Whitney LW, Massa PT (September 2001). "Specific deficiency in nuclear factor-kappaB activation in neurons of the central nervous system". Laboratory Investigation; A Journal of Technical Methods and Pathology. 81 (9): 1275-88. doi:10.1038/labinvest.3780341. PMID11555675.
^Moerman AM, Mao X, Lucas MM, Barger SW (April 1999). "Characterization of a neuronal kappaB-binding factor distinct from NF-kappaB". Brain Research. Molecular Brain Research. 67 (2): 303-15. doi:10.1016/s0169-328x(99)00091-1. PMID10216229.
^Escárcega RO, Fuentes-Alexandro S, García-Carrasco M, Gatica A, Zamora A (March 2007). "The transcription factor nuclear factor-kappa B and cancer". Clinical Oncology. 19 (2): 154-61. doi:10.1016/j.clon.2006.11.013. PMID17355113.
^Venuraju SM, Yerramasu A, Corder R, Lahiri A (May 2010). "Osteoprotegerin as a predictor of coronary artery disease and cardiovascular mortality and morbidity". Journal of the American College of Cardiology. 55 (19): 2049-61. doi:10.1016/j.jacc.2010.03.013. PMID20447527.
^Song XQ, Lv LX, Li WQ, Hao YH, Zhao JP (March 2009). "The interaction of nuclear factor-kappa B and cytokines is associated with schizophrenia". Biological Psychiatry. 65 (6): 481-8. doi:10.1016/j.biopsych.2008.10.018. PMID19058794.
^Kaisari S, Rom O, Aizenbud D, Reznick AZ (2013). "Involvement of NF-?B and muscle specific E3 ubiquitin ligase MuRF1 in cigarette smoke-induced catabolism in C2 myotubes". Advances in Experimental Medicine and Biology. 788: 7-17. doi:10.1007/978-94-007-6627-3_2. PMID23835952.
^Bonavita E, Galdiero MR, Jaillon S, Mantovani A (2015). "Phagocytes as Corrupted Policemen in Cancer-Related Inflammation". Advances in Cancer Research. 128: 141-71. doi:10.1016/bs.acr.2015.04.013. PMID26216632.
^Mantovani A, Marchesi F, Portal C, Allavena P, Sica A (2008). "Linking inflammation reactions to cancer: novel targets for therapeutic strategies". Advances in Experimental Medicine and Biology. 610: 112-27. doi:10.1007/978-0-387-73898-7_9. PMID18593019.
^Paur I, Balstad TR, Kolberg M, Pedersen MK, Austenaa LM, Jacobs DR, Blomhoff R (May 2010). "Extract of oregano, coffee, thyme, clove, and walnuts inhibits NF-kappaB in monocytes and in transgenic reporter mice". Cancer Prevention Research. 3 (5): 653-63. doi:10.1158/1940-6207.CAPR-09-0089. PMID20424131.
^Ding Y, Huang X, Liu T, Fu Y, Tan Z, Zheng H, Zhou T, Dai J, Xu W (October 2012). "The Plasmodium circumsporozoite protein, a novel NF-?B inhibitor, suppresses the growth of SW480". Pathology Oncology Research. 18 (4): 895-902. doi:10.1007/s12253-012-9519-7. PMID22678765.
^Cvek B, Dvorak Z (2007). "Targeting of nuclear factor-kappaB and proteasome by dithiocarbamate complexes with metals". Current Pharmaceutical Design. 13 (30): 3155-67. doi:10.2174/138161207782110390. PMID17979756.
^Yamamoto M, Horie R, Takeiri M, Kozawa I, Umezawa K (September 2008). "Inactivation of NF-kappaB components by covalent binding of (-)-dehydroxymethylepoxyquinomicin to specific cysteine residues". Journal of Medicinal Chemistry. 51 (18): 5780-8. doi:10.1021/jm8006245. PMID18729348.
^Kolati SR, Kasala ER, Bodduluru LN, Mahareddy JR, Uppulapu SK, Gogoi R, Barua CC, Lahkar M (March 2015). "BAY 11-7082 ameliorates diabetic nephropathy by attenuating hyperglycemia-mediated oxidative stress and renal inflammation via NF-?B pathway". Environmental Toxicology and Pharmacology. 39 (2): 690-9. doi:10.1016/j.etap.2015.01.019. PMID25704036.
^Kumar A, Negi G, Sharma SS (May 2012). "Suppression of NF-?B and NF-?B regulated oxidative stress and neuroinflammation by BAY 11-7082 (I?B phosphorylation inhibitor) in experimental diabetic neuropathy". Biochimie. 94 (5): 1158-65. doi:10.1016/j.biochi.2012.01.023. PMID22342224.